Literature DB >> 3389891

170H-progesterone rhythms in congenital adrenal hyperplasia.

M C Young1, J A Robinson, G F Read, D Riad-Fahmy, I A Hughes.   

Abstract

Serial blood spot and saliva samples were collected at home by 18 patients being treated for congenital adrenal hyperplasia to determine the circadian rhythm of 170H-progesterone as an index of therapeutic control. There was a strong correlation between the magnitude of the circadian fall and a single morning measurement of the plasma testosterone concentration taken near the time of the 170H-progesterone rhythm samples. Poor control in pubertal girls produced an exaggerated circadian fall in 170H-progesterone concentrations that were raised at all sampling times. Optimal control (plasma testosterone 1.5-2.5 nmol/l) was associated with blood spot and salivary 170H-progesterone concentrations at 0800 hours of between 30-70 nmol/l and 260-1000 pmol/l, respectively, falling thereafter to less than 10 nmol/l and less than 150 pmol/l, respectively. Similar results were obtained in prepubertal patients. Nomograms have been constructed to interpret the daily profiles of blood spot or salivary measurements of 170H-progesterone, or both. The analysis of 170H-progesterone circadian rhythms is useful in monitoring treatment in patients with congenital adrenal hyperplasia, particularly those who may be overtreated.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3389891      PMCID: PMC1778868          DOI: 10.1136/adc.63.6.617

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  13 in total

1.  Serum androgens as a continuing index of adequacy of treatment of congenital adrenal hyperplasia.

Authors:  S Korth-Schutz; R Virdis; P Saenger; D M Chow; L S Levine; M I New
Journal:  J Clin Endocrinol Metab       Date:  1978-03       Impact factor: 5.958

2.  Serum 17-alpha-hydroxyprogesterone, progesterone, estradiol, and testosterone in the diagnosis and management of congenital adrenal hyperplasia.

Authors:  B M Lippe; S H LaFranchi; N Lavin; A Parlow; J Coyotupa; S A Kaplan
Journal:  J Pediatr       Date:  1974-12       Impact factor: 4.406

3.  Effect of hydrocortisone dose schedule on adrenal steroid secretion in congenital adrenal hyperplasia.

Authors:  J Winterer; G P Chrousos; D L Loriaux; G B Cutler
Journal:  J Pediatr       Date:  1985-01       Impact factor: 4.406

4.  Hormonal changes in puberty III: Correlation of plasma dehydroepiandrosterone, testosterone, FSH, and LH with stages of puberty and bone age in normal boys and girls and in patients with Addison's disease or hypogonadism or with premature or late adrenarche.

Authors:  P C Sizonenko; L Paunier
Journal:  J Clin Endocrinol Metab       Date:  1975-11       Impact factor: 5.958

Review 5.  Genetics of adrenal steroid 21-hydroxylase deficiency.

Authors:  M I New; P W Speiser
Journal:  Endocr Rev       Date:  1986-08       Impact factor: 19.871

6.  Control in congenital adrenal hyperplasia monitored by frequent saliva 17OH-progesterone measurements.

Authors:  I A Hughes; G F Read
Journal:  Horm Res       Date:  1984

7.  Cortisol production rate. II. Normal infants, children, and adults.

Authors:  F M Kenny; C Preeyasombat; C J Migeon
Journal:  Pediatrics       Date:  1966-01       Impact factor: 7.124

8.  Diurnal variation in blood 17-hydroxyprogesterone concentrations in untreated congenital adrenal hyperplasia.

Authors:  J Sólyom
Journal:  Arch Dis Child       Date:  1984-08       Impact factor: 3.791

9.  A rapid assay for 17 alpha OH-progesterone in plasma, saliva and amniotic fluid using a magnetisable solid-phase antiserum.

Authors:  J Dyas; G F Read; T Guha-Maulik; I A Hughes; D Riad-Fahmy
Journal:  Ann Clin Biochem       Date:  1984-09       Impact factor: 2.057

10.  Circadian patterns of plasma cortisol, 17-hydroxyprogesterone, and testosterone in congenital adrenal hyperplasia.

Authors:  H Frisch; K Parth; E Schober; W Swoboda
Journal:  Arch Dis Child       Date:  1981-03       Impact factor: 3.791

View more
  15 in total

1.  Monitoring treatment in congenital adrenal hyperplasia.

Authors:  S Appan; P C Hindmarsh; C G Brook
Journal:  Arch Dis Child       Date:  1989-09       Impact factor: 3.791

Review 2.  Management of congenital adrenal hyperplasia.

Authors:  I A Hughes
Journal:  Arch Dis Child       Date:  1988-11       Impact factor: 3.791

3.  Response to treatment of congenital adrenal hyperplasia in infancy.

Authors:  M C Young; I A Hughes
Journal:  Arch Dis Child       Date:  1990-04       Impact factor: 3.791

4.  Effect of treatment on growth in congenital adrenal hyperplasia.

Authors:  O Ercan; S Hatemi; E Kutlu; N Turan
Journal:  Indian J Pediatr       Date:  2000-11       Impact factor: 1.967

5.  Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline.

Authors:  Phyllis W Speiser; Ricardo Azziz; Laurence S Baskin; Lucia Ghizzoni; Terry W Hensle; Deborah P Merke; Heino F L Meyer-Bahlburg; Walter L Miller; Victor M Montori; Sharon E Oberfield; Martin Ritzen; Perrin C White
Journal:  J Clin Endocrinol Metab       Date:  2010-09       Impact factor: 5.958

6.  Growth and body proportions in congenital adrenal hyperplasia.

Authors:  M C Young; J Ribeiro; I A Hughes
Journal:  Arch Dis Child       Date:  1989-11       Impact factor: 3.791

7.  Prevalence of congenital adrenal hyperplasia in Kuwait.

Authors:  M M Lubani; A R Issa; R Bushnaq; Q A al-Saleh; K I Dudin; P C Reavey; M Y el-Khalifa; D S Manandhar; Y K Abdul Al; E A Ismail
Journal:  Eur J Pediatr       Date:  1990-03       Impact factor: 3.183

8.  Dexamethasone treatment for congenital adrenal hyperplasia.

Authors:  M C Young; I A Hughes
Journal:  Arch Dis Child       Date:  1990-03       Impact factor: 3.791

9.  Androstenedione rhythms in saliva in congenital adrenal hyperplasia.

Authors:  M C Young; R F Walker; D Riad-Fahmy; I A Hughes
Journal:  Arch Dis Child       Date:  1988-06       Impact factor: 3.791

10.  Hormonal circadian rhythms in patients with congenital adrenal hyperplasia: identifying optimal monitoring times and novel disease biomarkers.

Authors:  Miguel Debono; Ashwini Mallappa; Verena Gounden; Aikaterini A Nella; Robert F Harrison; Christopher A Crutchfield; Peter S Backlund; Steven J Soldin; Richard J Ross; Deborah P Merke
Journal:  Eur J Endocrinol       Date:  2015-09-04       Impact factor: 6.664

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.